Phase 3 Clinical Trials With Primary Completion Dates in February 2019
This is a list of Phase 3 trials with primary completion dates in February 2019 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| AIMT | Aimmune Therapeutics, Inc. | 2019-02-01 | Phase 3 | NCT03337542 | AR101 Real-World Open-Label Extension Study |
| AIMT | Aimmune Therapeutics, Inc. | 2019-02-01 | Phase 3 | NCT03201003 | ARTEMIS Peanut Allergy In Children |
| ALNY | Alnylam Pharmaceuticals, Inc. | 2019-02-01 | Phase 3 | NCT03338816 | ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP) |
| ITCI | Intra-Cellular Therapies Inc. | 2019-02-01 | Phase 3 | NCT02600507 | Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression |
| MCRB | Seres Therapeutics, Inc. | 2019-02-01 | Phase 3 | NCT03183128 | ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection |
| MESO | Mesoblast Limited | 2019-02-01 | Phase 3 | NCT01233960 | Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease |
| PBYI | Puma Biotechnology Inc | 2019-02-01 | Phase 3 | NCT01808573 | A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting |
| PRAH | PRA Health Sciences, Inc. | 2019-02-01 | Phase 3 | NCT01550003 | Pediatric Arthritis Study of Certolizumab Pegol |
| PRTO | Proteon Therapeutics, Inc. | 2019-02-01 | Phase 3 | NCT02414841 | A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2) |
| TCDA | Tricida, Inc. | 2019-02-01 | Phase 3 | NCT03390842 | Long-term Safety Extension to Study TRCA-301 |
| URGN | UroGen Pharma Ltd. | 2019-02-01 | Phase 3 | NCT02793128 | The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study |